1986
Combined modality treatment of cutaneous T cell lymphoma: results of a 6-year follow-up.
Winkler C, Sausville E, Ihde D, Fischmann A, Schechter G, Kumar P, Nibhanupdi J, Minna J, Makuch R, Eddy J. Combined modality treatment of cutaneous T cell lymphoma: results of a 6-year follow-up. Journal Of Clinical Oncology 1986, 4: 1094-100. PMID: 3088220, DOI: 10.1200/jco.1986.4.7.1094.Peer-Reviewed Original ResearchConceptsTotal skin electron beam irradiationStage I patientsCutaneous T-cell lymphomaDisease-free survivalT-cell lymphomaI patientsStage IIComplete responseModality treatmentCell lymphomaStage IMedian disease-free survivalDisease-free survivorsThree-drug regimensCombined modality treatmentAdvanced-stage patientsOverall response rateOral corticosteroidsAdvanced diseaseSystemic chemotherapyProtocol treatmentTopical therapyStage patientsCR rateSimultaneous chemotherapyNon-small-cell lung cancer. Major cause of late mortality in patients with small cell lung cancer
Johnson B, Ihde D, Matthews M, Bunn P, Zabell A, Makuch R, Johnston-early A, Cohen M, Glatstein E, Minna J. Non-small-cell lung cancer. Major cause of late mortality in patients with small cell lung cancer. The American Journal Of Medicine 1986, 80: 1103-1110. PMID: 3014875, DOI: 10.1016/0002-9343(86)90672-8.Peer-Reviewed Original ResearchConceptsSmall cell lung cancerCell lung cancerLung cancer deathsLung cancerCancer deathSame lobeSecond primary lung tumorsCancer-free survivorsDisease-free survivalPrimary lung tumorsSecond malignant tumorsRisk of developmentLate mortalityContralateral lungTherapeutic trialsInitial lesionLung tumorsMalignant tumorsHigh riskPatientsCancerDifferent lobesMajor causeDiagnosisStudy of menPulmonary toxicity with combined modality therapy for limited stage small-cell lung cancer.
Brooks B, Seifter E, Walsh T, Lichter A, Bunn P, Zabell A, Johnston-Early A, Edison M, Makuch R, Cohen M. Pulmonary toxicity with combined modality therapy for limited stage small-cell lung cancer. Journal Of Clinical Oncology 1986, 4: 200-9. PMID: 3003259, DOI: 10.1200/jco.1986.4.2.200.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntineoplastic Combined Chemotherapy ProtocolsCarcinoma, Small CellCombined Modality TherapyCyclophosphamideDoxorubicinFemaleHumansLomustineLung NeoplasmsMaleMethotrexateMiddle AgedProcarbazinePrognosisProspective StudiesPulmonary FibrosisRadiographyRandom AllocationRespiratory Function TestsVincristineConceptsPulmonary function testsLimited stage small cell lung cancerStage small cell lung cancerSmall cell lung cancerModality therapyPulmonary toxicityPulmonary complicationsVital capacityLung cancerRadiation therapyLife-threatening pulmonary toxicityInitial pulmonary function testLower vital capacitySubsequent pulmonary complicationsBilateral pulmonary infiltratesDisease-free survivalModality armPulmonary infiltratesPulmonary morbidityExpiratory volumeOverall survivalPerformance statusProspective trialClinical courseHospital admission
1982
The clinical behavior of „mixed”︁ small cell/large cell bronchogenic carcinoma compared to „pure”︁ small cell subtypes
Radice P, Matthews M, Ihde D, Gazdar A, Carney D, Bunn P, Cohen M, Fossieck B, Makuch R, Minna J. The clinical behavior of „mixed”︁ small cell/large cell bronchogenic carcinoma compared to „pure”︁ small cell subtypes. Cancer 1982, 50: 2894-2902. PMID: 6291745, DOI: 10.1002/1097-0142(19821215)50:12<2894::aid-cncr2820501232>3.0.co;2-g.Peer-Reviewed Original ResearchConceptsSmall cell carcinomaSmall cell subtypeCell carcinomaResponse rateCombination chemotherapyClinical behaviorLong-term disease-free survivalCentral nervous system metastasesSmall cell carcinoma casesUntreated lung cancer patientsCell subtypesSmall cell lung cancerAggressive chemotherapy protocolsDistinct pathologic variantComplete response rateNervous system metastasesCell bronchogenic carcinomaDisease-free survivalIntensive combination chemotherapySmall cell cancerExtent of diseaseLarge cell carcinomaCell lung cancerLung cancer patientsLarge cell component
1980
Determination of prognostic factors and their influence on therapeutic results in patients with Ewing's sarcoma
Glaubiger D, Makuch R, Schwarz J, Levine A, Johnson R. Determination of prognostic factors and their influence on therapeutic results in patients with Ewing's sarcoma. Cancer 1980, 45: 2213-2219. PMID: 7370962, DOI: 10.1002/1097-0142(19800415)45:8<2213::aid-cncr2820450834>3.0.co;2-l.Peer-Reviewed Original ResearchConceptsDisease-free survivalPrognostic factorsEwing's sarcomaTreatment groupsLactic acid dehydrogenasePrimary diseaseSerum lactic acid dehydrogenaseSystemic chemotherapy regimensFavorable prognostic factorTime of presentationLactic acid dehydrogenase levelsNumber of patientsResults of treatmentNational Cancer InstituteLatest regimensChemotherapy regimensMetastatic diseaseFavorable prognosisMetastatic statusFavorable outcomeTherapeutic resultsDehydrogenase levelsTreatment protocolLocal irradiationCancer Institute
1979
Cyclic alternating combination chemotherapy for small cell bronchogenic carcinoma.
Cohen M, Ihde D, Bunn P, Fossieck B, Matthews M, Shackney S, Johnston-Early A, Makuch R, Minna J. Cyclic alternating combination chemotherapy for small cell bronchogenic carcinoma. Journal Of The National Cancer Institute 1979, 63: 163-70. PMID: 221114.Peer-Reviewed Original ResearchConceptsSmall cell bronchogenic carcinomaResistant drug combinationsCell bronchogenic carcinomaCR rateCombination chemotherapyComplete responseBronchogenic carcinomaDrug combinationsExtensive disease patientsLimited disease patientsProtocol-eligible patientsHigh-dose cyclophosphamideBrain radiation therapyDisease-free survivalComplete respondersDrug regimensProlong survivalInitial treatmentRadiation therapyPatientsVP-16ChemotherapyCarcinomaSequential useMonths